OSAKA, Japan & FLORHAM PARK, N.J.--(BUSINESS WIRE)--Nov 14, 2019-- Shionogi & Co., Ltd. (hereafter `Shionogi`) today announced the U.S. Food and Drug Administration (FDA) has approved FETROJA ® (cefiderocol) for patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following: susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex. Approval of this indication is based on limited clinical safety and efficacy data for FETROJA. `FETROJA will fill a...
|
